Therefore, TZDs have demonstrated promising results in NAFLD amelioration, mainly through the reduction of hepatic steatosis correlated with increased adiponectin levels, but their clinical use could be limited by poor activity on hepatic fibrosis and long-term deleterious effects. This evidence concerns the gene ADIPOQ and Hepatic steatosis.